Classement en actions
#38932
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Prix de l'action
$2.84
Dernière synchronisation: 2025-07-14
Capitalisation boursière
$729.71K
Changement (1 jour)
-0.70%
Échange OncoCyte Corporation (OCX)
Revenus pour OncoCyte Corporation (OCX)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de OncoCyte Corporation, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour OncoCyte Corporation de 2026 à 2026
Revenus à la fin de chaque année
| Année |
Revenus |
Changez |
|
Pas assez de données pour les dates fournies. |
Revenus d’entreprises similaires ou concurrentes
| Entreprise |
Revenus |
Différence de revenus |
Pays |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$10.11B |
-
|
BE
|
